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Background: Antiretroviral therapy (ART) in pregnancy has resulted in a marked impact on reducing the risk of
mother-to-child transmission (MCT) of HIV. However the safety of in utero ART exposure in newborns remains a
concern.
Methods: A multicenter prospective observational study of HIV-infected mother and their infants was performed in
Madrid, Spain, from 2000 to 2009. Children had regular visits with clinical examination according to protocol until
the age of 24 months. An abdominal ultrasound and an echocardiogram were scheduled during follow up. Birth
defects (BDs) were registered according to European Surveillance of Congenital Anomalies (EUROCAT).
Results: A total of 897 live births from 872 mothers were included. Overall the birth defects prevalence observed
was 6.9% (95% CI 5.4-9.1).The most commonly reported birth defects types were in genital organs and urinary
system (19 cases, 30.6%) and cardiovascular system (17 cases, 27.4%). There was no increased risk for infants
exposed in the first trimester to ARVs compared with unexposed infants. No significant associations were observed
between exposure to any individual antiretroviral agent during pregnancy and birth defects
Conclusion: A higher prevalence of BDs was observed, higher than previously reported. In utero exposure to ART
was not proved to be a major risk factor of birth defects in infants. However the relatively small number of patients
is a major limitation of this study.
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Antiretroviral therapy (ART) in pregnancy has a marked
impact on reducing the risk of mother-to-child transmis-
sion (MCT) of HIV [1]. In 1994, the use of zidovudine
(ZDV) given during pregnancy and delivery to the mother
and during the first weeks of life to the nonbreast-fed new-
born was demonstrated to reduce transmission by about
67% [2]. It is now recommended worldwide that HIV-
infected pregnant women receive combination ARV
regimens during pregnancy [3]. An increasing number
of pregnant women are receiving ART in Spain [4,5].
The use of HAART during pregnancy in Spain has
reduced the perinatal HIV transmission below 2% [5].* Correspondence: lmprieto.hugf@salud.madrid.org
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unless otherwise stated.There are concerns about potential adverse events in
newborns exposed to ART during pregnancy, including
birth defects. Different prevalences of birth defects
(BDs) have been reported in studies with large number
of subjects from Europe and United States. While some
studies have not detected an overall increase in the prev-
alences of birth defects (BDs) associated with ART
exposure in pregnancy [6,7], others studies have shown
an increased prevalence [8,9].
Some studies have reported elevated risks with specific
exposures. Nucleoside reverse transcriptase inhibitors
have a high transplacentary passage [10-12]. These drugs
have been associated with mitochondrial DNA depletion
and, in preliminary studies in monkeys, mitochondrial
toxicity has been found in the skeletal and cardiac muscles
and brain tissue [10,12]. A significantly increased preva-
lence of hypospadias following first trimester zidovudineThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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observed [13]. Recently, a specific association between in
utero exposure to zidovudine and heart defects have been
reported in the French Perinatal Cohort [14]. Likewise an
increased BDs prevalence in infants exposed to didanosine
in first trimester was reported by the Antiretroviral
Pregnancy Registry [6].
Exposure to efavirenz, a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) has been associated with
central nervous system defects in monkeys [15], and
case reports of neural tube defects in human patients
are concerning [16,17]. A recent meta-analysis has
not shown increased risk of birth defects, including
central nervous system defects, in newborns exposed
to efavirenz during the first trimester of pregnancy
(RR 0.85 (95% CI 0.61-1.20) [18]. This result was an
important consideration by WHO recommendation
for the use of efavirenz during pregnancy [19]. However
new data about central nervous system defects published,
beyond this meta-analysis, has been less reassuring in the
consideration of the use of EFV during first trimestrer of
pregnancy [14].
The continued surveillance of birth defects in newborns
exposed to antiretrovirals in utero is required, more even
when newer antiretroviral agents become available. The
aim of our study was to estimate the prevalence of birth
defects in children exposed in utero to ARV drugs and to
assess the association between in utero exposure to
antirretovirals and birth defects in the Madrid Cohort
of HIV-infected mother-infants pairs.
Methods
Study population
The Madrid Cohort of HIV-infected mother-infants
pairs is a multicenter prospective observational study of
HIV-infected pregnant women and their infants followed
up since birth. Beginning in 2000, pregnant women and
infants were recruited in 8 hospitals in Madrid, Spain.
All participants gave verbal informed consent and the
study was approved by the Clinical Research Ethics
Committee at Hospital Universitario de Getafe.
The baseline characteristics of the cohort and the mother-
to-child transmission of HIV data have been provided previ-
ously [5].A collaboration of infectious disease specialists,
gynaecologists and paediatricians provided prospective and
active follow-up as soon as pregnancy was detected in
previously monitored HIV-positive women, or as soon
as a pregnant woman was identified as HIV-positive, in
order to determine the mother-to-child transmission rate,
the effectiveness and safety of ART, the presence of
birth defects and age-appropriate development in children
follow-up.
The cohort for the current analyses includes pregnancies
with a definitive outcome through December 31, 2009.Characteristics of the study population and variables
Women were visited during pregnancy, at delivery and
at postpartum. Women with a previous diagnosis of HIV
infection were enrolled in the first visit of pregnancy.
Women who were diagnosed with HIV infection during
pregnancy were enrolled in the first visit after the diagnosis.
Information on maternal demographic characteristics was
recorded. At each visit, a medical history and a physical
examination was performed. Blood count, biochemistry
panel, HIV-1 viral load (plasma quantitative HIV-1 RNA
level) and CD4+ lymphocyte counts and percentage
were collected at each scheduled visit. Start and stop
dates were recorded for each antiretroviral agent
used. Maternal viral load less than 50 copies/ml was
defined as ‘undetectable’.
Trimesters of pregnancy were defined as follows:
first trimester, the first day of the last menstrual
period through 13 completed weeks of gestation; second
trimester, 14 through 28 completed weeks of gestation;
and third trimester, beginning at 29 weeks of gestation
until delivery.
ART in pregnant women was classified as: none, mono-
therapy with zidovudine, dual therapy and any combin-
ation of 3 or more drugs was categorized as HAART.
HAART was further categorized according to whether a
protease inhibitor (PI) or a nonnucleoside reverse
transcriptase inhibitor (NNRTI) was included. ART
treatment administered during pregnancy was recorded,
with the dates when started and stopped. Exposure status
for each drug was categorised as unexposed, exposed
during first trimester, or exposed since the second or
third trimester. Birth defects were studied associated
to exposure to each drug in first or since second or
third trimester compared to no exposure.
A self-report of illicit drug use or a positive urine test
result for heroin or opiates, methadone or cocaine was
registered. Other variables like cigarette smoking and
alcohol use were also self-reported. Diabetes was included
as a maternal condition in the analysis. However no other
drugs different from ARV were analysed.
Stillbirths and termination of pregnancy are not
considered in this analysis. Newborn/infant visits occurred
at birth, after 2 or 3 and 6 weeks and thereafter 3, 6,
12, 18 and 24 months. Children had regular visits
with clinical examination according to protocol until
the age of 24 months. Each visit included a medical
history and a physical examination. An abdominal
ultrasound was also performed in the first month of
life, and an echocardiogram during the first 24 months
of life by protocol.
‘Premature birth’ was defined as children born before
37 weeks of pregnancy. ‘Low birth weight’ was defined
as children born weighing from 1.500 to 2.500 g; ‘very
low birth weight’ was defined as 1.499 g or less.
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Birth defect was defined as a structural defect of the
body or organ system that may affect viability, quality of
life and often requiring surgery [20].
Abnormalities in the fetus/newborn/infant were deter-
mined from all available data, including prenatal ultra-
sound examinations, physical examinations in the newborn
period and at each follow-up visit.
Abnormalities observed in the active surveillance sys-
tem including abdominal ultrasound in neonatal period
or echocardiograms during follow-up, as scheduled in
the follow-up of this cohort, were also included.
BDs were recorded and classified according to EUROCAT
(European Surveillance of Congenital Anomalies) [21], a
simpler system than that proposed by the Antiretroviral
Pregnancy Registry (APR) [22]. A baby with multiple defects
was counted as a single outcome. Birth defects were
grouped according to an organ system classification: central
nervous system, eyes, face (including neck and ears),
hepatic/digestive, musculoskeletal (including cranial
bone alterations), cardiac, genitourinary, chromosomal,
extremities and others [23].
“Minor” anomalies are excluded, when isolated, because
they have lesser medical, functional or cosmetic conse-
quences. We also exclude anomalies which are not always
truly congenital in origin, sometimes associated with
immaturity at birth.
Angiomas, congenital nevi, pre-auricular appendices,
sinus nodules, sacral dimples, atresia of the tears ducts,
ovarian cysts, hydrocele, hip dislocation not associated
to dysplasia, renal pelvis dilatation of less than 10 mm
(without hydronephrosis or urethral atresia), inguinal
and umbilical hernias were not classified as BDs and
therefore also not included.
These cases have not been reported previously to the
Antiretroviral Pregnancy Registry or any other regulatory
authorithy.
Statistical analysis
The categorical variables were expressed as frequencies
and percentages, while numerical variables were presented
as means, medians, standard deviation, and interquartile
range. The categorical variables were compared using the
chi square, linear tendency chi square or Fisher’s exact test
when considered appropriate. Continuous variables were
analyzed with ANOVA test, or, in case of non normal
distributions, using a non-parametric test. Regression
logistic model was used to estimate the strength of
association between birth defect and ARV trimester
exposure. Results are presented as crude and adjusted
odds ratio and 95% confidence intervals (CIs) adjusted for
alcohol and illegal drug use during pregnancy. All p values
are two-sided p-values and a p value of < 0.05 was consid-
ered as statistically significant. The data were analysedwith the SPSS (Chicago, IL) program, version 15.0 for
Windows.
Results
Maternal and infants characteristics and antiretroviral
therapy
During the study period 898 children, including 25 twins
or triplets, were considered for this analysis.
The baseline characteristics of the mothers by anti-
retroviral exposure (exposure in first trimester, exposure
in second/third trimester, no antiretroviral exposure in
pregnancy) are compared in Table 1. The median gesta-
tional age at inclusion was 12 weeks (interquartile range
8–19 months). Women receiving ART during first tri-
mester were more likely to be white and older. Women
without antiretroviral therapy were more likely to use
illicit drugs or to drink alcohol.
Women had a good immunological condition status
at baseline, and there was no significant difference
observed in CD4 lymphocyte counts between the three
groups.
Eighty women (8.9%) did not receive treatment during
pregnancy. For those who treatment was known during
pregnancy, ten women (1.2%) received monotherapy
with zidovudine; 21 women (2,6%) received dual therapy
(zidovudine plus lamivudine or nevirapine) and 709 (86.6%)
received HAART. More than a third of infants (36.7%) had
early in-utero exposure.
Four hundred and seventy one infants (52.9%) were
males. The median gestational age was 38 completed
weeks [interquartile range (IQR): 37–39 weeks]. One
hundred and ninety four infants were premature
(22.8%); 221 infants (25.6%) presented low weight at
birth. The median time of follow-up of the children was
18 months (interquartile range 12–24 months).
Birth defects
Among the study population, major birth defects were
recorded in 62 infants, presenting an overall prevalence
of 6.9% (95% CI: 5.3-8.7). There were 70 anomalies
identified in these 62 infants. Minor defects, classified
according EUROCAT, were excluded.
The prevalence of birth defects among HIV-infected
women with first-trimester antiretroviral exposure was
7.0% (95% CI: 4.5-10.3). No significant differences were
found in the BD prevalence of children receiving intra-
uterine ART during the first trimester of pregnancy
compared with those who started later [7.0% (23/329)
vs 6.8% (39/568); p = 1.00] or those non exposed to
antiretroviral treatment during pregnancy [7.0% (23/329)
vs 7.5% (6/80); p = 0.80].
The most commonly reported birth defects were in
genital organs and urinary system (19 cases, 30.6%),
cardiovascular system (17 cases, 27.4%), musculoskeletal








Mean age (y) (n = 825) 33.3 30.3 29.8 <0.001
Race (n = 898) < 0.001
Caucasian 279 (84.8%) 307(62.9%) 41 (51.2%)
Sub-Saharan 33 (10.0%) 95 (19.5%) 27 (33.7%)
Latino American 13 (4.0%) 74 (15.2%) 9 (11.2%)
Others 4 (1.2%) 12 (2.4%) 3 (3.8%)
Smoking during pregnancy 123 (41.8%) 136 (30.8%) 11 (16.1%) 0.05
Alcohol use during pregnancy (n = 696) 10 (3.6%) 16 (4.4%) 8 (16.3%) < 0.001
Illegal drug use during pregnancy (n = 750) 22 (7.4%) 35 (8.9%) 17 (27.9%) < 0.001
CD4+ lymphocyte count at enrolment (n = 554) 0.61
>500 cells/μl 121 (48.2%) 123 (42.7%) 6 (40%)
200-500 cells/μl 103 (41.0%) 127 (44.1%) 8 (53.3%)
<200 cells/μl 27 (10.8%) 38 (13.2%) 1 (6.7%)
HIV RNA levels to delivery (n = 642) <0,001
<50 copies /ml 224 (81.4%) 245 (70.6%)
>50 copies/ml 51 (18.6%) 102 (29.4%) 20 (100%)
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(Table 2).
The risk of birth defects was not significantly associ-
ated with maternal age or ethnic origin. There were no
differences either with smoking or using illicit drugs
during pregnancy. When we analyzed immunological
and virological factors no differences were found in BD
prevalences associated with maternal CD4 lymphocytes
count in first trimester or maternal viral load in third
trimester (Table 3).
Birth defects were associated with low birth weight in
our cohort (11.3 vs 5.4%, p < 0.01) but although there
was a slight difference, the association did not reach
significance for preterm delivery (9.8 vs 6.1%, p = 0.07).
The type of treatment received by their mothers
(none, monotherapy, dual therapy or HAART) was
not associated with BD (Table 3).
In analysis there was no significant association with
exposure to specific drugs. (Table 4). There were 42
infants exposed in utero to efavirenz; three of them,
(7.1%) had birth defects. This percentage did not differ
significantly from the prevalence of BD in infants without
efavirenz exposure [7.1% (3/42) versus 7.0% (56/793);
p = 1.00]. Only two children exposed to EFV in first
trimester had BD (two hydronephrosis). No central
nervous system anomalies were observed in infants
exposed in utero to efavirenz. Two hundred eighty-seven
children were exposed to ZDV in first trimester. Eighteen
children exposed to ZDV in first trimester had BD (eight
patients with birth defects in genital organs and urinary
system and seven with birth defects in cardiovascularsystem). Two of the three cases of hypospadias were in
infants exposed to zidovudine in utero. Fifty-nine children
were exposed to ddI in first trimester and five of them
were exposed to ddI in first trimester had BD (8.4%)
We observed a high prevalence of defects after atazanavir
exposure, even when we broke down this result by
trimester of exposure (16.7% in first trimester and
15.8% in second/third trimester). The defect after atazana-
vir exposure in first trimester was oesophageal atresia, and
the defects after atazanavir exposure in second/third
trimester were Pierre Robin syndrome, hydronephrosis
and atrial septal defect.
As we observed differences between baseline characteris-
tics of HIV infected mothers and time of earliest antiretro-
viral therapy during pregnancy, we analysed the association
between birth defect and ARV treatment exposure
adjusted for age, alcohol and illegal drug use, but not
significant differences were found (Table 4).
Discussion
A major birth defects prevalence of 6.9% was observed in
this cohort. This population of infants born to HIV-infected
women was similar to other European cohorts in aspects
such as the characteristics of the mothers and rates of
perinatal HIV transmission. However, the prematurity
rates in our cohort are higher than in other cohorts
[1,5,24-26]. The prevalence of BD in this cohort is higher
than previously described. Knapp et al. compared different
European [27,28] and American studies [8,13,29]
evaluating ARV exposure and congenital anomalies and
observed a prevalence from 1.5 to 6.1% [9] Overall in most
Table 2 Listing of birth defects detected by timing of
antiretroviral therapy exposure









Microcephaly 0 1 0
Face/neck/eyes/ears
Morrie syndrome 0 1 0
Microphthalmia 1 0 0
Coloboma 0 0 1
Syndromic facies 1§ 0 0
Cardiovascular and
circulatory defects





















Alagille syndrome 0 2# 0
Oesophageal atresia 1‡ 0 0
Diaphragmatic hernia 1 0 0
Genital organs
Cryptorchidism 3 1 2
Double urethra 0 1 0
Vaginal polyp 1 0 0
Urinary system
Hydronephrosis 2 5 0





Premature synostosis 1 1 0
Clubfeet 0 1 0







Table 2 Listing of birth defects detected by timing of
antiretroviral therapy exposure (Continued)
Limbs
Syndatyly 0 1 0












*Includes one case with atrial septal defect.
#Both patients also had tracheal stenosis.
†This patient also had hydronephrosis.
‡This patient also had vertebral bodies abnormalities and left superior
caval vein.
§This patient also had blepharophimosis and developmental delay.
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for BD based on physical examinations during scheduled
visits.
A difference has to be established between passive
surveillance systems (most of which only recording
defects based on physical examinations detected in
scheduled visits) and active surveillance systems,
which include ultrasound scans and echocardiogram
in all infants with follow-up from birth. Active surveillance
systems, usually show higher BD prevalences. In more
than thirty thousand of German newborns not exposed to
ART, an active vigilance study showed a BD prevalence of
6.9% [30].
We have reported 17 cardiac malformations, including
9 atrial septal defects and 4 ventricular septal defects.
Some authors have reported that early screening
echocardiography can detect important subclinical
malformations and produce prevalences of cardiac defects
of 5% to 10% higher than expected [31,32]. We also
reported two hepatic vascular anomalies and a renal
duplicity, detected by ultrasonography. These BDs may
not have been otherwise detected in a passive surveillance
study. However we could not measure the impact of an
active surveillance system used in our cohort.
There are obviously ethnic and environmental fac-
tors related to BDs. However we could not show any
association between ethnic group and BD in our cohort
(Table 3). In previous studies in Spanish general
population in the last ten years, BDs prevalence was
2% based on two classification systems [33,34]. Although
these results differs considerably from the BD preva-
lence published in our study, they were not based on
EUROCAT classification system. In these registries either
systematic ultrasounds or long follow-up of the children
were not included.




N % N %
Maternal age at enrolment (n = 825)
<20 years 14 1.7 2 14.3 0.43
20-35 years 577 69.9 38 6.6
≥35 years 234 28.4 19 8.1
Maternal ethnic origin (n = 897)
Caucasian 628 69.9 46 7.3 0.94
Latino American 96 10.7 6 6.3
Sub Saharan 155 17.3 9 5.8
Other 18 2.1 1 5.5
Smoking during pregnancy (n = 680) 0.45
Yes 270 39.7 17 6.2
No 410 60.3 33 8.0
Alcohol during pregnancy (n = 696) 0.73
Yes 34 4.9 3 8.8
No 662 95.1 49 7.4
Drugs (cocaine, heroin, methadone)
(n = 750)
0.78
Yes 74 9.9 6 8.1
No 676 90.1 49 7.2
Maternal diabetes (n = 876)
Yes 51 5.8 6 11.8 0.16
No 825 94.2 56 6.8
Maternal CD4 lymphocytes in 1st
trimester (n = 554)
<200 cells/μl 66 11.9 6 9.1 0.29
200-500 cells/μl 238 43.0 14 5.9
>500 cells/μl 250 45.1 24 9.6
Maternal viral load in 3rd trimester
(n = 642)
>50 copies/ml 173 26.9 16 9.2 0.92
<50 copies/ml 469 73.1 28 6.0
Treatment in first trimester (n = 897) 1.00
Yes 329 36.7 23 7.0
No 568 63.3 39 6.8
Mother’s treatment group (n = 818) 0.24
Untreated 78 9.5 6 7.7
Monotherapy 10 1.2 1 10.0
Dual therapy 21 2.6 4 19.0
HAART including PI 476 58.2 31 6.5
HAART not including PI 233 28.5 14 6.0
Gestational age (weeks) (n = 850) 0.07
>37 656 77.2 40 6.1
<37 194 22.8 19 9.8
Table 3 Risk factors for congenital abnormalities
(Continued)
Newborn sex (n = 890) 0.75
Male 471 52.9 34 7.2
Female 419 47.1 28 6.7
Birth weight (n = 863) 0.003
>2,500 g 642 74.4 35 5.4
<2,500 g 221 25.6 25 11.3
HAART, highly active antiretroviral treatment; PI, protease inhibitor.
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heart defects have been previously associated. Based on
these results, it has been suggested that an underlying
mechanism or a genetic disorder could explain this
association [35]. We could not report the association
between preterm delivery and BD (9.8 vs 6.1%, p = 0.07),
but we have observed an association with low weight at
birth (11.3 vs 5.4%, p < 0.01). Interestingly, in our cohort
40% (25 cases) of BD were observed in patients with low
weight at birth.
The use of illicit drugs during pregnancy (cocaine,
heroine or methadone) was not associated with BD. Two
cases of foetal alcoholic syndrome were documented.
Mothers of these two children reported to consume large
amounts of alcohol. However, we could not observe an
association between alcohol consumption and BD.
Alcohol was a self-reported variable, and it was an
important limitation for its analysis.
We did not detect any significant association between
BD prevalence and type or timing of ART in pregnancy.
First-trimester antiretroviral exposure was not significantly
associated with birth defects. This fact is consistent with
most of the reports concerning BD and ART, which do not
show an increased risk of teratogenesis in infants exposed
to ART in the first trimester of pregnancy. However, others
studies have found higher rates of BD associated a specific
ARV drugs. Exposure to zidovudine in first trimester
have been associated to higher prevalence of hypospadias
[13] but also to heart defects [14]. In our study, we
included more than 200 children with ZDV exposure
in first trimester, and we didn’t observe an increased
risk of BD. However in the French Perinatal Cohort
with more than 3000 children exposed to ZDV in
first trimester, a significant association was found with
congenital heart defects.
According to the type of drug used (Table 4), no
significant increase in BD prevalence was found for
each drug, not even with EFV (6.67% in intrautero
exposed infants vs 8.33% in no exposed infants; p = 0.98)
neither ddI (8.47% vs 13.16%; p =0.27). In the case of
atazanavir the rates were higher, but that because of the
small number of women exposed, the confidence intervals
were large and it was not possible to conclude.




























Zidovudine 18/287 (6.27%) 20/269 (7.43%) 19/289 (6.57%) 0.85 0.95 (0.48; 1.85) 1.21 (0.56;2.63) 1.14 (0.59; 2.18) 0.83 (0.43; 1.61)
Lamivudine 22/338 (6.51%) 17/285 (5.96%) 19/227 (8.37%) 0.54 0.76 (0.40; 1.44) 0.87 (0.42; 1.82) 0.69 (0.35; 1.36) 1.09 (0.57; 2.10)
Stavudine 7/96 (7.29%)* 3/48 (6.25%) 48/687 (6.99%) 0.97 1.04 (0.45; 2.38) 1.15 (0.49; 2.66) 0.88 (0.26; 2.96) 1.17 (0.29; 4.78)
Didanosine 5/59 (8.47%)* 5/38 (13.16%) 48/734 (6.54%) 0.27 1.32 (0.50; 3.46) 1.25 (0.42; 3.67) 2.16 (0.80; 5.79) 0.61 (0.16; 2.27)
Abacavir 4/73 (5.48%)* 3/18 (16.67%) 51/744 (6.85%) 0.24 0.78 (0.27; 2.24) 0.99 (0.34; 2.87) 2.71 (0.76; 9.69) 0.28 (0.05; 1.43)
Tenofovir 4/58 (6.90%)* 1/22 (4.55%) 54/755 (7.15%) 0.89 0.96 (0.33; 2.75) 1.01 (0.30; 3.42) 0.61 (0.08; 4.68) 1.55 (0.16; 14.73)
Emtricitabine 1/19 (5.26%)* 0/15 (0.00%) 58/807 (7.19%) 0.53 0.71 (0.09; 5.46) NA NA NA
NNRTI
Nevirapine 7/150 (4.67%)* 3/85 (3.53%) 47/611 (7.69%) 0.19 0.58 (0.26; 1.32) 0.53 (0.22; 1.30) 0.43 (0.13; 1.44) 1.33 (0.33; 5.31)
Efavirenz 2/30 (6.67%)* 1/12 (8.33%) 56/793 (7.06%) 0.98 0.94 (0.21; 4.04) 1.04 (0.23; 4.55) 1.19 (0.15; 9.43) 0.78 (0.06; 9.56)
PI
Nelfinavir 11/127(8.66%)* 11/141 (7.80%) 36/562 (6.41%) 0.61 1.38 (0.68; 2.80) 1.56 (0.73; 3.34) 1.23 (0.61; 2.49) 1.12 (0.46; 2.68)
Saquinavir 1/40 (2.50%)* 1/28 (3.57%) 56/766 (7.31%) 0.39 0.32 (0.04; 2.41) NA 0.46 (0.06; 3.52) 0.69 (0.04; 11.55)
Lopinavir/r 5/86 (5.81%)* 3/51 (5.88%) 51/696 (7.33%) 0.82 0.78 (0.30; 2.01) 0.88 (0.30; 2.55) 0.79 (0.23; 2.62) 0.98 (0.22; 4.31)
Indinavir 4/21 (19.05%)* 1/10 (10%) 54/810 (6.67%) 0.08 3.29 (0.92; 10.13) 3.74(0.94; 11.89) 1.55 (0.19; 12.50) 2.11 (0.20; 21.88)
Atazanavir 1/6 (16.67%)* 3/19 (15.79%) 50/780 (6.41%) 0.16 2.92 (0.33; 25.47) 3.27(0.68; 15.73) 2.73 (0.77; 9.70) 1.06 (0.08; 12.68)
Fosamprenavir 0/4 (0%)* 0/3 (0%) 59/837 (7.05%) 0.86 NA NA NA NA
Tipranavir 0/1 (0%)* 0/0 59/843 (7.00%) 0.78 NA NA NA NA
Other ARVs
Enfuvirtide 0/0* 0/1 (0%) 59/846 (6.97%) 0.78 NA NA NA
Raltegravir 0/0* 0/1 (0%) 62/896 (6.92%) 0.79 NA NA NA
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor. NA not applicable/no child in
this category.
*First trimester exposures less than 200 for each agent.
aP values are global p-value for the three categories in each type of exposure. P values were calculated using chi square test and Fisher’s exact test. bOR obtained
by univariate logistic regression. cAOR obtained by multivariate logistic regression adjusted for age, alcohol and illegal drug use during pregnancy.
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indinavir and head and neck defects. In our cohort,
we observed a higher prevalence of defects in children
exposed to indinavir in the first trimester, however, this
difference did not reach significance and did not concern
head or neck defects.
This study has several limitations. In prospective cohorts
the confounding factors are not sufficiently controlled and
can lead to bias due to the interpretation of the results. We
have not consider for analysis stillbirths and termination of
pregnancy. Data as smoking or using illicit drugs during
pregnancy were self reported. Also no other drugs used
during pregnancy were analysed in this report. The major
limitation of our study is the small number of children
exposed to ARV in first trimester. We have not analysed
any association of specific BDs with each ARV drug. For this
reason, no conclusion could be assessed when the number
of exposures in first trimester is low. Cohort collaborations
and long term follow up are required to further analysis.Conclusion
In conclusion, a higher prevalence on BDs in infants born
to HIV-infected women was observed in this report.
However, in utero exposure to ART was not associated to
BD. The relatively small number of patients is a major
limitation for further analysis in this study.
Appendix 1: Members of the Madrid Cohort of
HIV-Infected Mother-Infant Pairs
Hospital Universitario 12 de Octubre: MI González-Tomé,
E Muñoz, O Nieto, P Rojo, JM Hernández-García, R Rubio,
F Pulido, D Lora, A Gómez de la Cámara, M de Matías, B
Fraile, D Blázquez, LI González-Granado, A Navas.
Hospital Universitario La Paz: MI de José, JM Peña, M
González, MJ Mellado, L Escosa.
Hospital General Universitario Gregorio Marañón: ML
Navarro, J Saavedra, MD
Gurbindo, MC Viñuelas, P Miralles.
Hospital General de Móstoles: MA Roa, C Garaulet.
Prieto et al. BMC Infectious Diseases  (2014) 14:700 Page 8 of 9Hospital Severo Ochoa: I Olabarrieta, MJ Santos, N
Martínez, G Alonso.
Hospital Príncipe de Asturias: J Beceiro, S Oñate.
Hospital Ramón y Cajal: A Holguín, P Rojas, C
Fernández.
Hospital Universitario de Getafe: JT Ramos, B Soto, A
Álvarez, M Fernández Ibieta, S Guillén, E Iglesias, I
Cuadrado, I Solis, G Gaspar, L Prieto, I García de
Diego.
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